推进:对莱纳利多米德耐火性多发性骨髓瘤的第二线治疗选择
Katia Mancuso1,2, Simona Barbato1,2, Francesco Di Raimondo3
1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", 40138 Bologna, Italy.
Cancers
|April 14, 2025
概括
管理复发性/耐药性多发性骨髓瘤,特别是经过莱纳利多米德失败后,存在挑战. 新的治疗策略正在出现,以改善这些难以治疗的患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床治疗学 临床治疗学
背景情况:
- 多发性骨髓瘤的治疗场景已经发展,改善了患者的生存率和反应深度.
- 复发性/耐药性多发性骨髓瘤带来了挑战,先前的治疗影响了后续的选择.
- 莱纳利多米德的折射性与较差的结果有关,需要具体的管理策略.
研究的目的:
- 审查目前对勒纳利多米德耐火性多发性骨髓瘤的治疗选择.
- 讨论这个患者子组的新兴疗法和未来方向.
主要方法:
- 对当前治疗指南的文献综述.
- 对复发性/耐药性多发性骨髓瘤最近临床试验数据的分析.
- 基于现有证据的治疗策略的讨论.
主要成果:
- 对勒纳利多米德耐火性多发性骨髓瘤的治疗选择有限,但正在扩大.
- 最近的临床研究显示了新型治疗方法的有希望的结果.
- 对多种药物耐药性患者的管理仍然是一个关键的未满足需求.
结论:
- 优化莱纳利多米德耐火性多发性骨髓瘤的治疗是至关重要的.
- 新兴疗法为这一具有挑战性的患者群体提供了改善结果的希望.
- 目前正在进行的临床试验对于推进复发性/耐药性多发性髓瘤的治疗至关重要.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy
404
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
404
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)